Advair Panel Denies Survival Benefit, But Endorses Other Efficacy Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Pulmonary-Allergy Drugs Advisory Committee votes against evidence that GSK’s Advair increases survival, but agrees the combination product reduces exacerbations of COPD.